Clinical Evaluation of Mucin-1 (MUC1) and P16 in Laryngeal Cancer
Irmi Wiest1#, Christoph Alexiou2*, Klaus Friese1, Doris Mayr3, Christoph Freier1,4, Annika Stiasny1, Peter Betz5, Marina Pöttler2, Jutta Tübel6, Steffen Goletz7, Tobias Weißenbacher1, Darius Dian1, Udo Jeschke1 and Bernd Kost1
- *Corresponding Author:
- Christoph Alexiou
Department of Otorhinolaryngology
Head and Neck Surgery
Section for Experimental Oncology and Nanomedicine (SEON)
University Hospital Erlangen, Glückstr. 10a
Tel: +49 9131 85-33142
Fax: +49 9131 85-34808
E-mail: [email protected]
Received date: July 22, 2016; Accepted date: August 04, 2016; Published date: August 11, 2016
Citation: Wiest I, Alexiou C, Friese K, Mayr D, Freier C, et al. (2016) Clinical Evaluation of Mucin-1 (MUC1) and P16 in Laryngeal Cancer. Otolaryngol (Sunnyvale) 6:255. doi:10.4172/2161-119X.1000255
Copyright: ©2016 Wiest I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Adapted from results in the field of cervical cancer, a direct connection between HPV infection and oropharyngeal carcinoma development could be established. Aim of this study was to evaluate p16 and TA-MUC1 in laryngeal cancer and their correlation to diagnostic, since TA-MUC1 is primarily restricted to malignancies. Methods: Paraffin-embedded laryngeal cancer specimens (n=129) and normal tissue (n=5) were analyzed for TA-MUC1 expression using hPankoMab-GEXTM antibody and evaluated according the immunoreactive score. Survival was assessed via log-rank test and Kaplan-Meier-survival analysis. Results: Significant correlation with tumor grading and staging was exhibited by TA-MUC1staining, while being negative in normal tissues. Expression of p16 significantly increased in T4 compared to T1 tumors. Significant differences in overall survival were found in correlation to TNM-classification, grading and relapse. TA-MUC1 showed a positive trend correlating to p16. Conclusion: Because of this positive trend, we suggest a HPV association in head and neck tumors. Most likely due to an insufficient quantity of HPV-positive patients, no statistical significance could be established. However, targeting TA-MUC1 would improve tumor therapy by linking hPankoMab-GEXTM to the overexpressed galectin. Systematic analysis of HPV-association should be performed generally in laryngeal cancer to gain further information about the interaction of HPV and malignancies.